New Prospects for Molecular Targets for Chordomas

Mohammad Zeeshan Ozair, Pavan Pinkesh Shah, Dimitrios Mathios, Michael Lim, Nelson Moss

Research output: Contribution to journalReview articlepeer-review

Abstract

Chordomas are benign, highly recurrent tumors of the midline skeleton that arise from the remnants of the notochord. The development of systemic therapy is critically important to ultimately managing this tumor. Several ongoing trials are attempting to use molecular targeted therapies for mutated pathways in recurrent and advanced chordomas and have shown promise. In addition, immunotherapies, including brachyury-directed vaccination and checkpoint inhibition, have also been attempted with encouraging results. This article discusses the major pathways that have been implicated in the pathogenesis of chordoma with an emphasis on molecular vulnerabilities that future therapies are attempting to exploit.

Original languageEnglish (US)
Pages (from-to)289-300
Number of pages12
JournalNeurosurgery clinics of North America
Volume31
Issue number2
DOIs
StatePublished - Apr 2020

Keywords

  • Brachyury
  • Chordoma
  • Immunotherapy
  • Molecular targeted therapy
  • Notochord
  • Receptor tyrosine kinase (RTKs)

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint Dive into the research topics of 'New Prospects for Molecular Targets for Chordomas'. Together they form a unique fingerprint.

Cite this